Monash University

Restricted Access

Reason: Access restricted by the author. A copy can be requested for private research and study by contacting your institution's library service. This copy cannot be republished

Evaluation of the molecular mechanisms by which serelaxin mediates its anti-fibrotic actions

posted on 2020-07-23, 04:51 authored by CHAO WANG
Fibrosis (tissue scarring) is a hallmark of several cardiovascular diseases and cause of heart failure. Despite the significant burden of fibrosis, there are currently no effective cures for its regression. This thesis investigated novel signal transduction mechanisms by which the emerging anti-fibrotic drug, serelaxin, reduced fibrosis and related cardiac remodelling/function in primary human cardiac myofibroblasts (key fibrosis-producing cells) and a pre-clinical model of cardiomyopathy; and demonstrated the extent to which these cardioprotective effects of serelaxin could be enhanced by co-administration of the clinically-used anti-oxidant, N-Acetyl cysteine. These studies have contributed to developing serelaxin as a treatment for human heart diseases.


Principal supervisor

Chrishan Samuel

Additional supervisor 1

Barbara Kemp-Harper

Year of Award


Department, School or Centre

Biomedical Sciences (Monash Biomedicine Discovery Institute)

Additional Institution or Organisation


Campus location



Doctor of Philosophy

Degree Type



Faculty of Medicine, Nursing and Health Sciences